This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
April 18, 2024
BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim report Q1 2024
April 17, 2024
Oncopeptides publishes prospectus relating to the rights issue
April 15, 2024
Oncopeptides secures national reimbursement for Pepaxti in Spain
April 10, 2024
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
April 09, 2024
Fusion Pharmaceuticals Announces Presentation Of Interim Data From The Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 At The AACR Annual Meeting 2024
April 08, 2024
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease
April 08, 2024
Oncopeptides announces final terms for the fully guaranteed rights issue
April 04, 2024
Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024
April 04, 2024
Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024
April 04, 2024
Oncopeptides releases first quarter 2024 sales